| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 21 | 2016 | 303 | 3.550 |
Why?
|
| RNA, Small Interfering | 17 | 2017 | 391 | 1.900 |
Why?
|
| RNA Interference | 5 | 2017 | 225 | 1.420 |
Why?
|
| Cisplatin | 5 | 2016 | 70 | 1.270 |
Why?
|
| Antineoplastic Agents | 9 | 2016 | 756 | 1.010 |
Why?
|
| Apoptosis | 12 | 2015 | 1317 | 0.910 |
Why?
|
| Gene Expression Regulation, Neoplastic | 11 | 2016 | 781 | 0.880 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 2 | 2014 | 11 | 0.870 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2015 | 209 | 0.770 |
Why?
|
| Cell Proliferation | 11 | 2016 | 1149 | 0.770 |
Why?
|
| Xenograft Model Antitumor Assays | 7 | 2015 | 242 | 0.680 |
Why?
|
| Mice, Nude | 13 | 2015 | 323 | 0.670 |
Why?
|
| Cell Line, Tumor | 22 | 2016 | 2128 | 0.660 |
Why?
|
| Aptamers, Nucleotide | 1 | 2017 | 28 | 0.620 |
Why?
|
| Glioblastoma | 1 | 2017 | 49 | 0.600 |
Why?
|
| RNA-Binding Proteins | 3 | 2016 | 145 | 0.590 |
Why?
|
| Brain Neoplasms | 1 | 2017 | 105 | 0.570 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2016 | 33 | 0.570 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2015 | 52 | 0.530 |
Why?
|
| Apoptosis Regulatory Proteins | 3 | 2014 | 146 | 0.500 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2014 | 73 | 0.480 |
Why?
|
| Neoplasm Metastasis | 5 | 2013 | 211 | 0.470 |
Why?
|
| Protein Isoforms | 1 | 2013 | 121 | 0.440 |
Why?
|
| Leukemia, Promyelocytic, Acute | 2 | 2009 | 18 | 0.440 |
Why?
|
| Taxoids | 2 | 2011 | 36 | 0.420 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 7 | 2015 | 605 | 0.420 |
Why?
|
| Co-Repressor Proteins | 1 | 2011 | 15 | 0.400 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2011 | 32 | 0.400 |
Why?
|
| MicroRNAs | 1 | 2016 | 386 | 0.400 |
Why?
|
| Peroxiredoxins | 1 | 2009 | 10 | 0.360 |
Why?
|
| Genes, myc | 1 | 2009 | 28 | 0.360 |
Why?
|
| Down-Regulation | 3 | 2011 | 420 | 0.350 |
Why?
|
| Animals | 24 | 2017 | 14307 | 0.350 |
Why?
|
| Oxides | 2 | 2009 | 89 | 0.350 |
Why?
|
| Piperazines | 1 | 2009 | 109 | 0.340 |
Why?
|
| Pyrimidines | 1 | 2009 | 112 | 0.340 |
Why?
|
| Arsenicals | 2 | 2009 | 85 | 0.340 |
Why?
|
| Receptor, PAR-1 | 1 | 2008 | 9 | 0.340 |
Why?
|
| Mice | 18 | 2013 | 5668 | 0.330 |
Why?
|
| Humans | 32 | 2017 | 34853 | 0.330 |
Why?
|
| Female | 22 | 2016 | 19873 | 0.330 |
Why?
|
| Quinolinium Compounds | 2 | 1998 | 7 | 0.320 |
Why?
|
| Cell Division | 1 | 2008 | 296 | 0.320 |
Why?
|
| Melanoma | 1 | 2008 | 91 | 0.310 |
Why?
|
| Transcription Factors | 1 | 2011 | 653 | 0.280 |
Why?
|
| Disease-Free Survival | 3 | 2015 | 114 | 0.260 |
Why?
|
| Blotting, Western | 5 | 2015 | 834 | 0.250 |
Why?
|
| Receptor, EphB4 | 2 | 2015 | 3 | 0.240 |
Why?
|
| Gene Silencing | 7 | 2013 | 143 | 0.230 |
Why?
|
| RNA, Messenger | 3 | 2014 | 1152 | 0.230 |
Why?
|
| Autophagy | 2 | 2014 | 111 | 0.210 |
Why?
|
| Chromatin Immunoprecipitation | 2 | 2014 | 71 | 0.210 |
Why?
|
| Carcinoma | 3 | 2013 | 94 | 0.200 |
Why?
|
| Liposomes | 3 | 2011 | 107 | 0.200 |
Why?
|
| Adenosine Triphosphatases | 2 | 2013 | 78 | 0.200 |
Why?
|
| Cell Survival | 5 | 2015 | 818 | 0.190 |
Why?
|
| Tumor Cells, Cultured | 3 | 2014 | 480 | 0.190 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 2 | 2010 | 17 | 0.180 |
Why?
|
| Neoplasm Invasiveness | 3 | 2016 | 247 | 0.180 |
Why?
|
| Immunohistochemistry | 6 | 2011 | 859 | 0.170 |
Why?
|
| Base Sequence | 3 | 2009 | 932 | 0.170 |
Why?
|
| Intercalating Agents | 1 | 1997 | 12 | 0.160 |
Why?
|
| Growth Inhibitors | 1 | 1997 | 23 | 0.160 |
Why?
|
| Pancreatic Neoplasms | 2 | 2009 | 106 | 0.160 |
Why?
|
| Phosphatidylcholines | 3 | 2011 | 45 | 0.150 |
Why?
|
| Drug Carriers | 1 | 2017 | 121 | 0.140 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2016 | 28 | 0.140 |
Why?
|
| Tumor Burden | 3 | 2011 | 79 | 0.140 |
Why?
|
| Gene Expression Profiling | 3 | 2011 | 600 | 0.140 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 195 | 0.140 |
Why?
|
| 3' Untranslated Regions | 1 | 2016 | 67 | 0.140 |
Why?
|
| Erythropoietin | 1 | 2015 | 37 | 0.140 |
Why?
|
| src-Family Kinases | 2 | 2013 | 42 | 0.140 |
Why?
|
| Cell Movement | 3 | 2014 | 545 | 0.140 |
Why?
|
| Aged | 4 | 2016 | 6448 | 0.130 |
Why?
|
| Gene Knockdown Techniques | 1 | 2015 | 161 | 0.130 |
Why?
|
| DNA | 1 | 1997 | 549 | 0.130 |
Why?
|
| Repressor Proteins | 1 | 2016 | 226 | 0.120 |
Why?
|
| Middle Aged | 5 | 2016 | 9642 | 0.120 |
Why?
|
| Diamines | 1 | 2013 | 7 | 0.110 |
Why?
|
| Receptor, EphA2 | 2 | 2010 | 6 | 0.110 |
Why?
|
| Benzothiazoles | 1 | 2013 | 20 | 0.110 |
Why?
|
| RNA Splicing | 1 | 2013 | 36 | 0.110 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2013 | 33 | 0.110 |
Why?
|
| Organic Chemicals | 1 | 2013 | 35 | 0.110 |
Why?
|
| Membrane Transport Proteins | 1 | 2013 | 88 | 0.110 |
Why?
|
| Quinolines | 1 | 2013 | 60 | 0.110 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2013 | 82 | 0.110 |
Why?
|
| Gene Expression | 1 | 2015 | 639 | 0.110 |
Why?
|
| Neovascularization, Pathologic | 2 | 2009 | 122 | 0.110 |
Why?
|
| Crk-Associated Substrate Protein | 1 | 2011 | 3 | 0.110 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2011 | 298 | 0.100 |
Why?
|
| Promoter Regions, Genetic | 1 | 2014 | 484 | 0.100 |
Why?
|
| Carcinoid Tumor | 1 | 2011 | 3 | 0.100 |
Why?
|
| Neuroendocrine Tumors | 1 | 2011 | 5 | 0.100 |
Why?
|
| Microdissection | 1 | 2011 | 11 | 0.100 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2011 | 18 | 0.100 |
Why?
|
| Adult | 4 | 2016 | 11034 | 0.100 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2011 | 47 | 0.100 |
Why?
|
| Neoplastic Stem Cells | 1 | 2011 | 74 | 0.100 |
Why?
|
| Cytoskeleton | 1 | 2011 | 98 | 0.100 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2011 | 88 | 0.100 |
Why?
|
| Adrenergic Agents | 1 | 2010 | 8 | 0.090 |
Why?
|
| Centrosome | 1 | 2010 | 28 | 0.090 |
Why?
|
| Interleukin-8 | 1 | 2010 | 59 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2010 | 74 | 0.090 |
Why?
|
| Silicon | 1 | 2010 | 16 | 0.090 |
Why?
|
| Anoikis | 1 | 2010 | 21 | 0.090 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2009 | 9 | 0.090 |
Why?
|
| Adrenomedullin | 1 | 2009 | 4 | 0.090 |
Why?
|
| Signal Transduction | 7 | 2013 | 1802 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2011 | 178 | 0.090 |
Why?
|
| Receptors, Peptide | 1 | 2009 | 20 | 0.090 |
Why?
|
| Cation Transport Proteins | 1 | 2009 | 30 | 0.090 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2008 | 18 | 0.090 |
Why?
|
| Inhibitor of Differentiation Protein 2 | 1 | 2008 | 7 | 0.090 |
Why?
|
| Deoxycytidine | 1 | 2008 | 21 | 0.090 |
Why?
|
| Transcription Factor RelA | 1 | 2008 | 37 | 0.080 |
Why?
|
| DNA Primers | 1 | 2009 | 269 | 0.080 |
Why?
|
| Transglutaminases | 1 | 2008 | 8 | 0.080 |
Why?
|
| Benzofurans | 1 | 2008 | 19 | 0.080 |
Why?
|
| Neuralgia | 1 | 2008 | 13 | 0.080 |
Why?
|
| Eukaryotic Initiation Factor-4G | 1 | 2008 | 11 | 0.080 |
Why?
|
| Receptor, Cannabinoid, CB2 | 1 | 2008 | 33 | 0.080 |
Why?
|
| Piperidines | 1 | 2008 | 76 | 0.080 |
Why?
|
| Aged, 80 and over | 2 | 2015 | 2333 | 0.080 |
Why?
|
| Analgesics | 1 | 2008 | 56 | 0.080 |
Why?
|
| Drug Delivery Systems | 1 | 2009 | 182 | 0.080 |
Why?
|
| Enzyme Inhibitors | 1 | 2009 | 396 | 0.080 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2008 | 160 | 0.080 |
Why?
|
| Reactive Oxygen Species | 1 | 2009 | 416 | 0.070 |
Why?
|
| Norepinephrine | 3 | 2013 | 107 | 0.070 |
Why?
|
| Transplantation, Heterologous | 3 | 2011 | 87 | 0.070 |
Why?
|
| Phosphorylation | 4 | 2013 | 878 | 0.070 |
Why?
|
| Adenocarcinoma | 1 | 2008 | 239 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2008 | 195 | 0.070 |
Why?
|
| Nanoparticles | 1 | 2010 | 294 | 0.070 |
Why?
|
| Disease Progression | 3 | 2015 | 580 | 0.070 |
Why?
|
| Stress, Psychological | 1 | 2010 | 541 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 2015 | 1426 | 0.060 |
Why?
|
| Disease Models, Animal | 4 | 2010 | 1300 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2011 | 245 | 0.060 |
Why?
|
| HL-60 Cells | 2 | 2008 | 32 | 0.060 |
Why?
|
| Discrimination Learning | 1 | 2003 | 27 | 0.060 |
Why?
|
| Colorectal Neoplasms | 1 | 2008 | 413 | 0.060 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2010 | 107 | 0.060 |
Why?
|
| Up-Regulation | 3 | 2011 | 490 | 0.060 |
Why?
|
| Enzyme Activation | 2 | 2013 | 423 | 0.050 |
Why?
|
| Protein Binding | 2 | 2015 | 913 | 0.050 |
Why?
|
| Hippocampus | 1 | 2003 | 546 | 0.050 |
Why?
|
| Paclitaxel | 2 | 2010 | 48 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2014 | 1349 | 0.040 |
Why?
|
| DNA, Superhelical | 1 | 1998 | 7 | 0.040 |
Why?
|
| Etoposide | 1 | 1998 | 21 | 0.040 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1997 | 19 | 0.040 |
Why?
|
| HT29 Cells | 1 | 1997 | 40 | 0.040 |
Why?
|
| Viscosity | 1 | 1997 | 37 | 0.040 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 1997 | 19 | 0.040 |
Why?
|
| Nucleic Acid Conformation | 1 | 1998 | 142 | 0.040 |
Why?
|
| Hela Cells | 1 | 1997 | 344 | 0.040 |
Why?
|
| Models, Biological | 2 | 2010 | 642 | 0.030 |
Why?
|
| Receptors, Erythropoietin | 1 | 2015 | 7 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1997 | 176 | 0.030 |
Why?
|
| Protein Kinases | 2 | 2008 | 91 | 0.030 |
Why?
|
| STAT3 Transcription Factor | 1 | 2015 | 80 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2015 | 485 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2014 | 91 | 0.030 |
Why?
|
| R-SNARE Proteins | 1 | 2013 | 4 | 0.030 |
Why?
|
| Qa-SNARE Proteins | 1 | 2013 | 9 | 0.030 |
Why?
|
| Golgi Apparatus | 1 | 2013 | 25 | 0.030 |
Why?
|
| Phosphoserine | 1 | 2013 | 18 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2013 | 50 | 0.030 |
Why?
|
| Tyrosine | 1 | 2013 | 109 | 0.030 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2013 | 70 | 0.030 |
Why?
|
| Fluorescent Dyes | 1 | 2013 | 173 | 0.030 |
Why?
|
| Cyclic AMP | 1 | 2013 | 125 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2013 | 322 | 0.030 |
Why?
|
| Carcinogenicity Tests | 1 | 2011 | 4 | 0.030 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2011 | 14 | 0.030 |
Why?
|
| Stress, Physiological | 1 | 2013 | 137 | 0.030 |
Why?
|
| Cell Hypoxia | 1 | 2011 | 55 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2011 | 170 | 0.030 |
Why?
|
| Necrosis | 1 | 2011 | 45 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2011 | 185 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 195 | 0.030 |
Why?
|
| Microvessels | 1 | 2011 | 31 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2011 | 143 | 0.030 |
Why?
|
| Pyrroles | 1 | 2011 | 54 | 0.020 |
Why?
|
| Sirolimus | 1 | 2011 | 58 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2011 | 84 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 1530 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2013 | 360 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2011 | 200 | 0.020 |
Why?
|
| Restraint, Physical | 1 | 2010 | 17 | 0.020 |
Why?
|
| Genome, Human | 1 | 2011 | 112 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 2010 | 36 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2011 | 81 | 0.020 |
Why?
|
| Vasoconstrictor Agents | 1 | 2010 | 38 | 0.020 |
Why?
|
| Antibodies, Neoplasm | 1 | 2010 | 16 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2011 | 121 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2010 | 75 | 0.020 |
Why?
|
| Epinephrine | 1 | 2010 | 35 | 0.020 |
Why?
|
| Transfection | 1 | 2011 | 496 | 0.020 |
Why?
|
| Cell Death | 1 | 2011 | 260 | 0.020 |
Why?
|
| Indoles | 1 | 2011 | 154 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 570 | 0.020 |
Why?
|
| Glucose | 1 | 2011 | 217 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2009 | 45 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2011 | 184 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2009 | 41 | 0.020 |
Why?
|
| Actins | 1 | 2010 | 142 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2009 | 32 | 0.020 |
Why?
|
| DNA Adducts | 1 | 2009 | 41 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2013 | 751 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2009 | 56 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2010 | 309 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 445 | 0.020 |
Why?
|
| Spinal Nerves | 1 | 2008 | 4 | 0.020 |
Why?
|
| Ligation | 1 | 2008 | 9 | 0.020 |
Why?
|
| Autoradiography | 1 | 2008 | 36 | 0.020 |
Why?
|
| Radioligand Assay | 1 | 2008 | 61 | 0.020 |
Why?
|
| Rats | 2 | 2008 | 3261 | 0.020 |
Why?
|
| Cricetulus | 1 | 2008 | 74 | 0.020 |
Why?
|
| CHO Cells | 1 | 2008 | 107 | 0.020 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 2008 | 18 | 0.020 |
Why?
|
| Ligands | 1 | 2009 | 317 | 0.020 |
Why?
|
| Granulocytes | 1 | 2008 | 28 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2008 | 114 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2008 | 126 | 0.020 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2008 | 40 | 0.020 |
Why?
|
| Cricetinae | 1 | 2008 | 217 | 0.020 |
Why?
|
| GTP-Binding Proteins | 1 | 2008 | 57 | 0.020 |
Why?
|
| Tretinoin | 1 | 2008 | 50 | 0.020 |
Why?
|
| Species Specificity | 1 | 2008 | 233 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2009 | 229 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2011 | 486 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2008 | 161 | 0.020 |
Why?
|
| Binding Sites | 1 | 2009 | 597 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2011 | 1442 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2008 | 392 | 0.020 |
Why?
|
| Lung | 1 | 2009 | 413 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2009 | 296 | 0.020 |
Why?
|
| Motor Activity | 1 | 2008 | 393 | 0.020 |
Why?
|
| Young Adult | 1 | 2015 | 4012 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 984 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2008 | 562 | 0.020 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 5 | 1 | 2003 | 2 | 0.010 |
Why?
|
| Mutation | 1 | 2008 | 1023 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2003 | 13 | 0.010 |
Why?
|
| Receptors, Opioid, delta | 1 | 2003 | 22 | 0.010 |
Why?
|
| Space Perception | 1 | 2003 | 31 | 0.010 |
Why?
|
| Rats, Long-Evans | 1 | 2003 | 86 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2003 | 125 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2003 | 139 | 0.010 |
Why?
|
| Maze Learning | 1 | 2003 | 100 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2003 | 430 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 2003 | 338 | 0.010 |
Why?
|
| Male | 2 | 2008 | 18870 | 0.010 |
Why?
|